Skip to main content
. 2010 Nov 10;2010(11):CD005197. doi: 10.1002/14651858.CD005197.pub3

Comparison 1. Cefepime vs. other.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 All‐cause mortality 21 3471 Risk Ratio (M‐H, Fixed, 95% CI) 1.39 [1.04, 1.86]
1.1 ceftazidime 9 1102 Risk Ratio (M‐H, Fixed, 95% CI) 1.52 [0.99, 2.33]
1.2 carbapenem 8 1570 Risk Ratio (M‐H, Fixed, 95% CI) 1.19 [0.73, 1.94]
1.3 piperacillin‐tazobactam 4 799 Risk Ratio (M‐H, Fixed, 95% CI) 1.52 [0.74, 3.13]
2 All‐cause mortality FDA data 21 3550 Risk Ratio (M‐H, Fixed, 95% CI) 1.37 [1.03, 1.83]
2.1 ceftazidime 9 1203 Risk Ratio (M‐H, Fixed, 95% CI) 1.49 [0.99, 2.26]
2.2 carbapenem 8 1548 Risk Ratio (M‐H, Fixed, 95% CI) 1.15 [0.70, 1.90]
2.3 piperacillin‐tazobactam 4 799 Risk Ratio (M‐H, Fixed, 95% CI) 1.52 [0.74, 3.13]
3 All‐cause mortality ‐ sensitivity analysis allocation concealment 21 3471 Risk Ratio (M‐H, Fixed, 95% CI) 1.39 [1.04, 1.86]
3.1 adequate 9 1869 Risk Ratio (M‐H, Fixed, 95% CI) 1.74 [1.18, 2.56]
3.2 unclear 9 1382 Risk Ratio (M‐H, Fixed, 95% CI) 1.05 [0.65, 1.68]
3.3 inadequate 3 220 Risk Ratio (M‐H, Fixed, 95% CI) 0.67 [0.11, 3.95]
4 All‐cause mortality ‐ sensitivity analysis allocation generation 21 3471 Risk Ratio (M‐H, Fixed, 95% CI) 1.39 [1.04, 1.86]
4.1 adequate 10 1978 Risk Ratio (M‐H, Fixed, 95% CI) 1.79 [1.22, 2.64]
4.2 unclear 7 1233 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.58, 1.56]
4.3 inadequate 4 260 Risk Ratio (M‐H, Fixed, 95% CI) 1.01 [0.26, 3.92]
5 All‐cause mortality ‐ sensitivity analysis blinding 21 3471 Risk Ratio (M‐H, Fixed, 95% CI) 1.39 [1.04, 1.86]
5.1 open 15 2074 Risk Ratio (M‐H, Fixed, 95% CI) 1.16 [0.76, 1.76]
5.2 outcome assessor blinded 5 1121 Risk Ratio (M‐H, Fixed, 95% CI) 1.49 [0.89, 2.51]
5.3 double blind 1 276 Risk Ratio (M‐H, Fixed, 95% CI) 2.05 [1.01, 4.16]
6 All‐cause mortality ‐ sensitivity analysis intention to treat 21 3471 Risk Ratio (M‐H, Fixed, 95% CI) 1.39 [1.04, 1.86]
6.1 intention to treat 16 2435 Risk Ratio (M‐H, Fixed, 95% CI) 1.48 [1.05, 2.09]
6.2 per protocol 5 1036 Risk Ratio (M‐H, Fixed, 95% CI) 1.15 [0.64, 2.07]
7 All‐cause mortality ‐ sensitivity analysis publication status (data) 21 3471 Risk Ratio (M‐H, Fixed, 95% CI) 1.39 [1.04, 1.86]
7.1 published data 6 956 Risk Ratio (M‐H, Fixed, 95% CI) 1.92 [1.14, 3.22]
7.2 unpublished data 15 2515 Risk Ratio (M‐H, Fixed, 95% CI) 1.18 [0.82, 1.70]
8 All‐cause mortality ‐ sensitivity analysis publication status (publication) 21 3471 Risk Ratio (M‐H, Fixed, 95% CI) 1.39 [1.04, 1.86]
8.1 published paper 15 2013 Risk Ratio (M‐H, Fixed, 95% CI) 1.51 [1.02, 2.25]
8.2 unpublished paper 6 1458 Risk Ratio (M‐H, Fixed, 95% CI) 1.25 [0.81, 1.94]
9 All‐cause mortality ‐ sensitivity analysis dosing 21 3471 Risk Ratio (M‐H, Fixed, 95% CI) 1.39 [1.04, 1.86]
9.1 recommended dose ‐ allocation concealment A 7 1391 Risk Ratio (M‐H, Fixed, 95% CI) 1.64 [1.08, 2.50]
9.2 recommended dose ‐ allocation concealment B/C 9 1422 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.59, 1.55]
9.3 less than recommended dose 5 658 Risk Ratio (M‐H, Fixed, 95% CI) 2.09 [0.92, 4.77]
10 Infection related mortality 17 2632 Risk Ratio (M‐H, Fixed, 95% CI) 1.15 [0.74, 1.80]
10.1 ceftazidime 7 951 Risk Ratio (M‐H, Fixed, 95% CI) 1.10 [0.58, 2.07]
10.2 carbapenem 5 832 Risk Ratio (M‐H, Fixed, 95% CI) 0.85 [0.33, 2.18]
10.3 piperacillin‐tazobactam 5 849 Risk Ratio (M‐H, Fixed, 95% CI) 1.58 [0.69, 3.62]
11 Clinical failure 21 3028 Risk Ratio (M‐H, Fixed, 95% CI) 1.02 [0.95, 1.09]
11.1 ceftazidime 9 1087 Risk Ratio (M‐H, Fixed, 95% CI) 1.00 [0.92, 1.08]
11.2 carbapenem 7 1092 Risk Ratio (M‐H, Fixed, 95% CI) 0.93 [0.79, 1.11]
11.3 piperacillin‐tazobactam 5 849 Risk Ratio (M‐H, Fixed, 95% CI) 1.12 [0.99, 1.27]
12 Clinical failure ‐ allocation concealment sensitivity analysis 21 3078 Risk Ratio (M‐H, Fixed, 95% CI) 1.02 [0.96, 1.09]
12.1 adequate 9 1783 Risk Ratio (M‐H, Fixed, 95% CI) 1.05 [0.97, 1.15]
12.2 unclear 9 1075 Risk Ratio (M‐H, Fixed, 95% CI) 0.97 [0.87, 1.08]
12.3 inadequate 3 220 Risk Ratio (M‐H, Fixed, 95% CI) 1.06 [0.73, 1.52]
13 Failure for clinically documented infections 11 280 Risk Ratio (M‐H, Fixed, 95% CI) 1.09 [0.89, 1.35]
13.1 ceftazidime 5 147 Risk Ratio (M‐H, Fixed, 95% CI) 1.06 [0.74, 1.52]
13.2 carbapenem 5 112 Risk Ratio (M‐H, Fixed, 95% CI) 1.17 [0.85, 1.62]
13.3 piperacillin‐tazobactam 1 21 Risk Ratio (M‐H, Fixed, 95% CI) 0.97 [0.73, 1.29]
14 Microbiological failure 15 670 Risk Ratio (M‐H, Fixed, 95% CI) 0.97 [0.81, 1.15]
14.1 ceftazidime 7 225 Risk Ratio (M‐H, Fixed, 95% CI) 0.93 [0.75, 1.16]
14.2 carbapenem 5 319 Risk Ratio (M‐H, Fixed, 95% CI) 1.09 [0.82, 1.45]
14.3 piperacillin‐tazobactam 3 126 Risk Ratio (M‐H, Fixed, 95% CI) 0.66 [0.32, 1.37]
15 Any modifications 10 983 Risk Ratio (M‐H, Fixed, 95% CI) 1.00 [0.88, 1.13]
15.1 ceftazidime 7 712 Risk Ratio (M‐H, Fixed, 95% CI) 1.00 [0.87, 1.16]
15.2 carbapenem 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.3 piperacillin‐tazobactam 3 271 Risk Ratio (M‐H, Fixed, 95% CI) 0.97 [0.75, 1.26]
16 Glycopeptide addition 10 1322 Risk Ratio (M‐H, Fixed, 95% CI) 0.91 [0.75, 1.11]
16.1 ceftazidime 5 631 Risk Ratio (M‐H, Fixed, 95% CI) 0.99 [0.75, 1.31]
16.2 carbapenem 2 269 Risk Ratio (M‐H, Fixed, 95% CI) 0.59 [0.39, 0.90]
16.3 piperacillin‐tazobactam 3 422 Risk Ratio (M‐H, Fixed, 95% CI) 1.14 [0.79, 1.64]
17 Antifungal drug addition 9 1022 Risk Ratio (M‐H, Fixed, 95% CI) 0.92 [0.69, 1.22]
17.1 ceftazidime 4 527 Risk Ratio (M‐H, Fixed, 95% CI) 1.11 [0.76, 1.63]
17.2 carbapenem 3 318 Risk Ratio (M‐H, Fixed, 95% CI) 0.58 [0.31, 1.08]
17.3 piperacillin‐tazobactam 2 177 Risk Ratio (M‐H, Fixed, 95% CI) 0.93 [0.52, 1.66]
18 Superinfection ‐ any 7 1025 Risk Ratio (M‐H, Fixed, 95% CI) 0.87 [0.57, 1.33]
18.1 ceftazidime 5 570 Risk Ratio (M‐H, Fixed, 95% CI) 0.88 [0.52, 1.49]
18.2 carbapenem 2 455 Risk Ratio (M‐H, Fixed, 95% CI) 0.84 [0.40, 1.74]
18.3 piperacillin‐tazobactam 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Superinfection ‐ bacterial 5 780 Risk Ratio (M‐H, Fixed, 95% CI) 1.70 [0.94, 3.09]
19.1 ceftazidime 3 325 Risk Ratio (M‐H, Fixed, 95% CI) 2.13 [0.93, 4.87]
19.2 carbapenem 2 455 Risk Ratio (M‐H, Fixed, 95% CI) 1.34 [0.56, 3.23]
19.3 piperacillin‐tazobactam 0 0 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 Adverse events ‐ any 13 1879 Risk Ratio (M‐H, Fixed, 95% CI) 0.88 [0.80, 0.98]
20.1 ceftazidime 7 786 Risk Ratio (M‐H, Fixed, 95% CI) 0.96 [0.87, 1.06]
20.2 carbapenem 5 1043 Risk Ratio (M‐H, Fixed, 95% CI) 0.71 [0.56, 0.91]
20.3 piperacillin‐tazobactam 1 50 Risk Ratio (M‐H, Fixed, 95% CI) 2.0 [0.19, 20.67]
21 Adverse events requiring discontinuation 16 2355 Risk Ratio (M‐H, Fixed, 95% CI) 1.39 [0.87, 2.22]
21.1 ceftazidime 8 1062 Risk Ratio (M‐H, Fixed, 95% CI) 1.55 [0.92, 2.59]
21.2 carbapenem 4 756 Risk Ratio (M‐H, Fixed, 95% CI) 0.77 [0.21, 2.82]
21.3 piperacillin‐tazobactam 4 537 Risk Ratio (M‐H, Fixed, 95% CI) 1.04 [0.07, 16.18]